Abstract
Transformation suppressor Pdcd4 is downregulated in transformed (Tx) mouse epidermal JB6 RT101 cells relative to transformation-resistant (P−) and susceptible (P+) variants. Whether Pdcd4 downregulation is necessary not only to induce transformation but also to maintain tumor phenotypes has not been determined previously. In the present study, overexpression of Pdcd4 cDNA in stably transfected RT101 cells resulted in 40% fewer anchorage-independent colonies that were smaller in size than the vector control colonies, indicating that elevated Pdcd4 expression is sufficient to suppress tumor phenotype. Transient transfection of Pdcd4 expression plasmid and 4 × AP-1 reporter gene showed that activation of AP-1-dependent transcription was inhibited by Pdcd4 expression in a concentration-dependent manner. In contrast, Pdcd4 did not inhibit serum response element-dependent transcription, indicating specificity. In a Gal4 fusion assay, Pdcd4 specifically inhibited activation of c-Jun and c-Fos activation domains, but did not inhibit activation of JunB, JunD, Fra-1, or Fra-2. Gel mobility shift assay demonstrated that c-Jun is the major component detected in the AP-1 complex in RT101 cells. Previous studies suggested that AP-1 activity is required for maintaining the transformed phenotype in RT101 cells. Thus, Pdcd4 suppresses tumor phenotype by inhibiting AP-1-dependent transcription, possibly through inhibiting c-Jun and c-Fos activation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Angel P, Szabowski A and Schorpp-Kistner M . (2001). Oncogene, 20, 2413–2423.
Azzoni L, Zatsepina O, Abede B, Bennett IM, Kanakaraj P and Perussia B . (1998). J. Immunol., 161, 3493–3500.
Bernstein LR and Walker SE . (1999). Biochim. Biophys. Acta, 1489, 263–280.
Chauhan D, Auclair D, Robinson EK, Hideshima T, Li GL, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC and Anderson KC . (2002). Oncogene, 21, 1346–1358.
Chinenov Y and Kerppola TK . (2001). Oncogene, 20, 2438–2452.
Cmarik JL, Min H, Hegamyer G, Zhan S, Kulesz-Martin M, Yoshinaga H, Matsuhashi S and Colburn NH . (1999). Proc. Natl. Acad. Sci. USA, 96, 14037–14042.
Colburn NH . (1980). Carcinogen. Compr. Surv., 5, 33–56.
Colburn NH, Former BF, Nelson KA and Yuspa SH . (1979). Nature, 281, 589–591.
Colburn NH, Wendel EJ and Abruzzo G . (1981). Proc. Natl. Acad. Sci. USA, 78, 6912–6916.
Coussens LM, Fingleton B and Matrisian LM . (2002). Science, 295, 2387–2392.
Domann FE, Levy JP, Birrer MJ and Bowden GT . (1994). Cell Growth Differ., 5, 9–16.
Dong Z, Lavrovsky V and Colburn NH . (1995a). Carcinogenesis, 16, 749–756.
Dong Z, Watts RG, Sun Y, Zhan S-N and Colburn N . (1995b). Int. J. Oncol., 7, 359–364.
Holt JT, Gopal TV, Moulton AD and Nienhuis AW . (1986). Proc. Natl. Acad. Sci. USA, 83, 4794–4798.
Hsu TC, Nair R, Tulsian P, Camalier CE, Hegamyer GA, Young MR and Colburn NH . (2001). Cancer Res., 61, 4160–4168.
Hsu TC, Young MR, Cmarik J and Colburn NH . (2000). Free Radic. Biol. Med., 28, 1338–1348.
Kazumi S and Colburn NH . (2002). Oncogene, 21, 2181–2190.
Kovary K and Bravo R . (1991). Mol. Cell. Biol., 11, 4466–4472.
Li JJ, Cao Y, Young MR and Colburn NH . (2000). Mol. Carcinogen., 29, 159–169.
Li JJ, Rhim JS, Schlege R, Vousden KH and Colburn NH . (1998). Oncogene, 28, 2711–2721.
Liu Y, Ludes-Meyers J, Zhang Y, Munoz-Medellin D, Kim HT, Lu C, Ge G, Schiff R, Hilsenbeck SG, Osborne CK and Brown PH . (2002). Oncogene, 21, 7680–7689.
Nishikura K and Murray JM . (1987). Mol. Cell. Biol., 7, 639–649.
Onishi Y and Kizaki H . (1996). Biochem. Biophys. Res. Commun., 228, 7–13.
Ozanne BW, McGarry L, Spence HJ, Johnston I, Winnie J, Meagher L and Stapleton G . (2000). Eur. J. Cancer, 36, 1640–1648.
Pause A, Methot N, Svitkin Y, Merrick WC and Sonenberg N . (1994). EMBO J., 13, 1205–1215.
Rapp UR, Troppmair J, Beck T and Birrer MJ . (1994). Oncogene, 9, 3493–3498.
Rogers Jr GW, Komar AA and Merrick WC . (2002). Prog. Nucleic Acid Res. Mol. Biol., 72, 307–331.
Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, Karin M, Angel P and Wagner EF . (1999). Genes Dev., 13, 607–619.
Schutte J, Minna JD and Birrer MJ . (1989a). Proc. Natl. Acad. Sci. USA, 86, 2257–2261.
Schutte J, Viallet J, Nau M, Segal S, Fedorko J and Minna J . (1989b). Cell, 59, 987–997.
Shaulian E and Karin M . (2001). Oncogene, 20, 2390–2400.
Shaulian E and Karin M . (2002). Nat. Cell. Biol., 4, E131–E136.
Shibahara K, Asano M, Ishida Y, Aoki T, Koike T and Honjo T . (1995). Gene, 166, 297–301.
Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH and Birrer MJ . (1999). Oncogene, 18, 6063–6070.
Suzuki T, Murakami M, Onai N, Fukuda E, Hashimoto Y, Sonobe MH, Kameda T, Ichinose M, Miki K and Iba H . (1994). J. Virol., 68, 3527–3535.
Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G, Belsham GJ and Sonenberg N . (2001). RNA, 7, 382–394.
Takahashi K, Heine UI, Junker JL, Colburn NH and Rice JM . (1986). Cancer Res., 46, 5923–5932.
Watts RG, Ben-Ari ET, Bernstein LR, Birrer MJ, Winterstein D, Wendel E and Colburn NH . (1995). Mol. Carcinogen., 13, 27–36.
Yang HS, Jansen AP, Komar AA, Zheng X, Merrick WC, Costes S, Lockett SJ, Sonenberg N and Colburn NH . (2003). Mol. Cell. Biol., 23, 26–37.
Yang HS, Jansen AP, Nair R, Shibahara K, Verma AK, Cmarik JL and Colburn NH . (2001). Oncogene, 20, 669–676.
Young MR, Nair R, Bucheimer N, Tulsian P, Brown N, Chapp C, Hsu TC and Colburn NH . (2002). Mol. Cell. Biol., 22, 587–598.
Zhang ZH and DuBois RN . (2001). Oncogene, 20, 4450–4456.
Acknowledgements
We thank the members of the Gene Regulation Section for helpful discussions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, HS., Knies, J., Stark, C. et al. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 22, 3712–3720 (2003). https://doi.org/10.1038/sj.onc.1206433
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206433
Keywords
This article is cited by
-
MiR-181a protects the heart against myocardial infarction by regulating mitochondrial fission via targeting programmed cell death protein 4
Scientific Reports (2024)
-
A comprehensive review on oncogenic miRNAs in breast cancer
Journal of Genetics (2021)
-
Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis
Hormones and Cancer (2020)
-
A novel mechanism for the control of translation of specific mRNAs by tumor suppressor protein Pdcd4: inhibition of translation elongation
Oncogene (2015)
-
Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine
BMC Systems Biology (2014)